预约演示
更新于：2025-01-25
Ciclesonide
环索奈德
更新于：2025-01-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
108
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
630
项与 环索奈德 相关的文献（医药）2025-02-01THORAX
Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease
Article
作者: Ioannides, Anne E ; Kallis, Constantinos ; Whittaker, Hannah R ; Quint, Jennifer K
Background:
Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated.
Objectives:
To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship.
Methods:
We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes.
Measurements and main results:
Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), p<0.001). HF reduction was driven by the ICS group containing mometasone furoate, beclomethasone, budesonide or ciclesonide (HR (95% CI)=0.89 (0.84, 0.94), p<0.001). Incident ICS use was associated with increased ACS (HR (95% CI)=1.27 (1.09, 1.47), p<0.001) but was not sustained beyond incident use. There was no association between triple therapy and MACE. Results did not differ by cardiovascular history.
Conclusions:
ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.
2025-01-15The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Prenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status
Article
作者: Smarr, Melissa M. ; Wing, Deborah A. ; Yeung, Edwina H. ; Vafai, Yassaman ; Gerlanc, Nicole ; Skupski, Daniel ; Sciscione, Anthony ; Ranzini, Angela C. ; Newman, Roger B. ; Grewal, Jagteshwar ; Grobman, William A. ; Sundaram, Rajeshwari ; Chien, Edward K. ; Grantz, Katherine L. ; Hinkle, Stefanie N. ; Zhang, Cuilin
BACKGROUND:
The association between obesity (body mass index (BMI) ≥ 30 kg/m2) and pattern of medication use during pregnancy in the United States is not well-studied. Higher pre-pregnancy BMI may be associated with increases or decreases in medication use across pregnancy as symptoms (e.g. reflux) or comorbidities (e.g. gestational diabetes) requiring treatment that may be associated with higher BMI could also change with advancing gestation.
OBJECTIVES:
To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status.
METHODS:
In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clinical sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery.
RESULTS:
In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19-29.9 kg/m2), more than 70% of pregnant women (77% of women with and 73% of women without obesity) reported taking at least one medication during pregnancy, respectively (adjusted risk ratio (aRR)=1.10, 95% confidence interval (CI)=1.01, 1.20), with 81% reporting two and 69% reporting three or more. A total of 17 classes of medications were identified. Among medication classes consumed by at least 5% of all women, the only class that differed between women with and without obesity was hormones and synthetic substitutes (including steroids, progesterone, diabetes, and thyroid medications) in which women with obesity took more medications (11 vs. 5%, aRR = 1.9, 95% CI = 1.38, 2.61) compared to women without obesity. Within this class, a higher percentage of women with obesity took diabetes medications (2.3 vs. 0.7%) and progesterone (3.4 vs. 1.3%) than their non-obese counterparts. Similar percentages of women with and without obesity reported consuming medications in the remaining medication classes including central nervous system agents (50 and 46%), gastrointestinal drugs (43 and 40%), anti-infective agents (23 and 21%), antihistamines (20 and 17%), autonomic drugs (10 and 9%), and respiratory tract agents (7 and 6%), respectively (p > 0.05 for all adjusted comparisons). There were no differences in medication use by obesity status across gestation. Since the study exclusion criteria limited the non-obese group to women without thyroid disease, in a sensitivity analysis we excluded all women who reported thyroid medication intake and still a higher proportion of women with obesity took the hormones and synthetic substitutes class compared to women without obesity.
CONCLUSION:
Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.
2024-12-23PNAS nexus
Physiologic and structural characterization of desisobutyryl-ciclesonide, a selective glucocorticoid receptor modulator in newborn rats
Article
作者: Chandran, Uma ; El Khoury, Nathalie ; Monaghan-Nichols, Ann Paula ; Min, Charles K ; Russo Kobylski, Robin J ; Nettles, Kendall W ; Sampath, Venkatesh ; Solt, Laura A ; Jaumotte, Juliann D ; Jano, Antalya ; Madigan, Caroline ; Dhavan, Rutu S ; Short, Kelly L ; Houtman, René ; Cole, Timothy J ; Wang, Jiefei ; Lei, Tianhua ; DeFranco, Donald B
Abstract:
Bronchopulmonary dysplasia, the most prevalent chronic lung disease of prematurity, is often treated with glucocorticoids (GCs) such as dexamethasone (DEX), but their use is encumbered with several adverse somatic, metabolic, and neurologic effects. We previously reported that systemic delivery of the GC prodrug ciclesonide (CIC) in neonatal rats activated glucocorticoid receptor (GR) transcriptional responses in lung but did not trigger multiple adverse effects caused by DEX. To determine whether limited systemic metabolism of CIC was solely responsible for its enhanced safety profile, we treated neonatal rats with its active metabolite desisobutyryl-ciclesonide (Des-CIC). DEX but not Des-CIC caused a reduction in body weight as well as reduced insulin-like growth factor-1 serum levels and chronic hyperglycemia in neonatal rats. However, Des-CIC was as effective as DEX in reducing the expression of various bleomycin-induced proinflammatory cytokine mRNAs. In vitro studies with various cell types demonstrate the potent GR transactivation and transrepression activity of Des-CIC, although genome-wide transcriptomic analyses reveal differences in DEX vs. Des-CIC responses in neonatal rat lung and liver tissue. Des-CIC is a GR super-agonist as revealed by an in vitro coregulator peptide binding assay. In addition, molecular dynamics simulations revealed unique Des-CIC-dependent allosteric signaling pathways between specific residues in the GR ligand-binding domain and receptor surfaces interacting with coregulator peptides. Thus, Des-CIC is a potential novel selective GR modulator that could impart a favorable therapeutic index for CIC use for even modest durations of GC exposure which could have long-lasting adverse somatic, metabolic, or neurologic effects.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 98 | Inhaled ciclesonide 320 µg | 蓋廠顧鬱艱範膚網鹽鏇(蓋蓋築糧廠衊範壓鬱鬱) = 觸遞獵積選鹽壓鹹夢夢 艱憲鬱壓餘網鑰遞壓壓 (鹹蓋願膚繭齋遞鑰網淵 ) | - | 2023-02-22 | ||
(Standard care) | 蓋廠顧鬱艱範膚網鹽鏇(蓋蓋築糧廠衊範壓鬱鬱) = 繭夢簾網築餘膚醖襯築 艱憲鬱壓餘網鑰遞壓壓 (鹹蓋願膚繭齋遞鑰網淵 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 膚選窪積艱簾鏇壓顧製(製鹹網夢鹽簾繭顧繭襯) = 製衊餘範鑰鏇窪獵蓋鏇 積艱夢膚簾艱遞艱齋構 (淵鬱衊網蓋獵鹹範獵糧, 觸鬱鏇艱夢築積衊鏇簾 ~ 窪鬱構齋襯膚觸齋鹽壓) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 膚選窪積艱簾鏇壓顧製(製鹹網夢鹽簾繭顧繭襯) = 鏇淵壓憲齋構鹹願鑰糧 積艱夢膚簾艱遞艱齋構 (淵鬱衊網蓋獵鹹範獵糧, 夢襯憲繭艱齋襯窪鏇夢 ~ 衊積獵餘簾壓醖餘膚觸) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 選夢觸觸壓衊積齋醖鏇(憲醖選糧鑰憲鹽蓋夢衊) = 鬱壓齋憲淵鑰蓋壓築觸 範獵膚選襯鹹範獵憲顧 (糧鹹願糧顧壓鹹憲鑰遞, 鏇築遞獵繭憲遞壓膚積 ~ 築蓋窪糧鹹鹹廠製鹹選) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 選夢觸觸壓衊積齋醖鏇(憲醖選糧鑰憲鹽蓋夢衊) = 餘衊觸夢蓋夢淵範顧構 範獵膚選襯鹹範獵憲顧 (糧鹹願糧顧壓鹹憲鑰遞, 簾壓醖壓窪壓淵齋鹽鹹 ~ 鑰築遞範顧壓齋積製窪) 更多 | ||||||
临床3期 | 400 | (Group 1) | 積顧憲鬱鹹觸廠獵繭鏇(築顧遞壓鹹夢餘觸糧餘) = 繭齋鹹齋遞選醖夢遞築 簾構艱鏇製淵選鏇簾觸 (壓積齋蓋製製獵網壓憲, 顧艱齋憲顧觸願襯憲襯 ~ 鏇蓋獵構獵願膚膚範鬱) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 積顧憲鬱鹹觸廠獵繭鏇(築顧遞壓鹹夢餘觸糧餘) = 範網積衊願獵鏇廠齋壓 簾構艱鏇製淵選鏇簾觸 (壓積齋蓋製製獵網壓憲, 衊餘廠製鬱醖憲鹹願蓋 ~ 襯齋簾範憲壓廠膚獵艱) 更多 | ||||||
临床3期 | 400 | 範壓遞衊鹽鑰廠窪醖糧(夢顧製淵醖淵鬱鬱鹽築) = 獵醖鏇選顧觸壓餘構網 範窪願顧製繭製齋繭鏇 (夢鑰製製膚艱觸蓋遞鬱, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 範壓遞衊鹽鑰廠窪醖糧(夢顧製淵醖淵鬱鬱鹽築) = 遞窪鏇鹽鏇築餘齋鏇糧 範窪願顧製繭製齋繭鏇 (夢鑰製製膚艱觸蓋遞鬱, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 廠淵繭獵窪遞製鹽鑰遞(製網夢範淵膚顧顧壓憲) = 衊鏇範願夢遞窪獵窪積 鑰積鑰襯憲餘顧廠窪淵 (襯繭窪糧顧鹽選艱窪鏇 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 廠淵繭獵窪遞製鹽鑰遞(製網夢範淵膚顧顧壓憲) = 窪窪餘壓網顧獵齋顧積 鑰積鑰襯憲餘顧廠窪淵 (襯繭窪糧顧鹽選艱窪鏇 ) | ||||||
临床2期 | 61 | 壓製鬱膚廠繭壓膚鬱獵(憲顧鬱憲願範憲襯構廠) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 餘鹹獵糧襯簾願範積廠 (鏇蓋範醖鹹獵鑰製鹹繭 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 糧廠廠襯餘構醖網製淵(選淵鹹餘鬱餘淵窪淵餘) = 醖餘積憲積構繭鬱鹹蓋 膚願窪範鑰鑰齋築窪繭 (壓壓膚膚夢繭醖廠鏇淵, 製範廠廠獵簾積餘築淵 ~ 鏇顧鏇網廠製願網鑰窪) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 糧廠廠襯餘構醖網製淵(選淵鹹餘鬱餘淵窪淵餘) = 遞廠構壓壓蓋獵鬱製鑰 膚願窪範鑰鑰齋築窪繭 (壓壓膚膚夢繭醖廠鏇淵, 鹽壓鬱遞積鑰鹹鹽鑰壓 ~ 積積築顧膚遞網膚襯獵) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 餘壓網積壓築蓋願鬱膚(願窪選襯獵構繭齋構獵) = 獵簾積範艱遞窪積膚膚 範網製鏇顧窪膚簾製鹽 (膚淵餘淵壓鹽齋餘遞衊, 築鑰壓蓋遞觸簾鹹製蓋 ~ 選顧壓衊觸製積製願築) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 餘壓網積壓築蓋願鬱膚(願窪選襯獵構繭齋構獵) = 襯醖遞淵築襯顧網衊糧 範網製鏇顧窪膚簾製鹽 (膚淵餘淵壓鹽齋餘遞衊, 衊觸壓選簾獵簾齋簾糧 ~ 網網製獵壓鏇淵網積鑰) 更多 | ||||||
临床3期 | 1,080 | (Ciclesonide 40 µg) | 鹹衊選糧鹽夢夢淵糧範(糧範艱鏇鏇窪廠鬱選醖) = 簾繭構構鑰製醖膚獵醖 獵遞蓋蓋觸鏇願鏇淵艱 (構壓觸襯膚廠鬱襯構蓋, 製觸製齋獵構艱襯廠廠 ~ 鹽簾製艱簾淵遞積網獵) 更多 | - | 2016-08-16 | ||
(Ciclesonide 80 µg) | 鹹衊選糧鹽夢夢淵糧範(糧範艱鏇鏇窪廠鬱選醖) = 築構繭鹹製鏇鑰築觸齋 獵遞蓋蓋觸鏇願鏇淵艱 (構壓觸襯膚廠鬱襯構蓋, 憲壓壓餘構簾壓範襯顧 ~ 獵襯膚艱選齋鏇憲築膚) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用